Identifying and definitional attributes | |
Metadata item type: | Data Element |
---|---|
Short name: | Cholesterol—total (measured) |
METEOR identifier: | 270403 |
Registration status: | Health, Superseded 01/10/2008 |
Definition: | A person's total cholesterol (TC), measured in mmol/L. |
Data Element Concept: | Person—cholesterol level |
Value Domain: | Total millimoles per litre N[N].N |
Data element attributes | |
Collection and usage attributes | |
Guide for use: | Measurement in mmol/L to 1 decimal place. Record the absolute result of the total cholesterol measurement. When reporting, record whether or not the measurement of Cholesterol-total - measured was performed in a fasting specimen. |
---|---|
Collection methods: | When reporting, record absolute result of the most recent Cholesterol-total - measured in the last 12 months to the nearest 0.1 mmol/L. Measurement of lipid levels should be carried out by laboratories, or practices, which have been accredited to perform these tests by the National Association of Testing Authorities.
|
Comments: | In settings where the monitoring of a person's health is ongoing and where a measure can change over time (such as general practice), the Service contact—service contact date, DDMMYYYY should be recorded. High blood cholesterol is a key factor in heart, stroke and vascular disease, especially coronary heart disease. Poor nutrition can be a contributing factor to heart, stroke and vascular disease as a population's level of saturated fat intake is the prime determinant of its level of blood cholesterol. Large clinical trials have shown that people at highest risk of cardiovascular events (e.g. pre-existing ischaemic heart disease) will derive the greatest benefit from lipid lowering drugs. For this group of patients, the optimum threshold plasma lipid concentration for drug treatment is still a matter of research. In May 1999 the PBS threshold total cholesterol concentration, for subsidy of drug treatment, was reduced from 5.5 to 4.0 mmol/L. (Australian Medical Handbook). |
Source and reference attributes | |
Submitting organisation: | Cardiovascular Data Working Group |
Origin: | National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand, Lipid Management Guidelines - 2001, MJA 2001; 175: S57-S88 National Health Priority Areas Report: Cardiovascular Health 1998. AIHW Cat. No. PHE 9. HEALTH and AIHW, Canberra. The Royal College of Pathologists of Australasia web based Manual of Use and Interpretation of Pathology Tests |
Relational attributes | |
Related metadata references: | Has been superseded by Person—cholesterol level (measured), total millimoles per litre N[N].N Health, Standard 01/10/2008 Is used in the formation of Person—low-density lipoprotein cholesterol level (calculated), total millimoles per litre N[N].N Health, Standard 01/10/2008 Is used in the formation of Person—low-density lipoprotein cholesterol level (calculated), total millimoles per litre N[N].N Health, Superseded 01/10/2008 Is re-engineered from Cholesterol-total - measured, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (21.4 KB) No registration status |
Implementation in Data Set Specifications: | Acute coronary syndrome (clinical) DSS Health, Superseded 07/12/2005 Acute coronary syndrome (clinical) DSS Health, Superseded 01/10/2008 Cardiovascular disease (clinical) DSS Health, Superseded 15/02/2006 DSS specific information: Scientific studies have shown a continuous relationship between lipid levels and coronary heart disease and overwhelming evidence that lipid lowering interventions reduce coronary heart disease progression, morbidity and mortality. Studies show a positive relationship between an individual's total blood cholesterol level and risk of coronary heart disease as well as death (Kannel & Gordon 1970; Pocock et al. 1989). Many studies have demonstrated the significance of blood cholesterol components as risk factors for heart, stroke and vascular disease. Several generalisations can be made from these cholesterol lowering trials:
There is high level evidence that in patients with existing coronary heart disease, lipid intervention therapy reduces the risk of subsequent stroke Cardiovascular disease (clinical) DSS Health, Superseded 04/07/2007 DSS specific information: Scientific studies have shown a continuous relationship between lipid levels and coronary heart disease and overwhelming evidence that lipid lowering interventions reduce coronary heart disease progression, morbidity and mortality. Studies show a positive relationship between an individual's total blood cholesterol level and risk of coronary heart disease as well as death (Kannel & Gordon 1970; Pocock et al. 1989). Many studies have demonstrated the significance of blood cholesterol components as risk factors for heart, stroke and vascular disease. Several generalisations can be made from these cholesterol lowering trials:
There is high level evidence that in patients with existing coronary heart disease, lipid intervention therapy reduces the risk of subsequent stroke Cardiovascular disease (clinical) DSS Health, Superseded 22/12/2009 DSS specific information: Scientific studies have shown a continuous relationship between lipid levels and coronary heart disease and overwhelming evidence that lipid lowering interventions reduce coronary heart disease progression, morbidity and mortality. Studies show a positive relationship between an individual's total blood cholesterol level and risk of coronary heart disease as well as death (Kannel & Gordon 1970; Pocock et al. 1989). Many studies have demonstrated the significance of blood cholesterol components as risk factors for heart, stroke and vascular disease. Several generalisations can be made from these cholesterol lowering trials:
There is high level evidence that in patients with existing coronary heart disease, lipid intervention therapy reduces the risk of subsequent stroke Diabetes (clinical) DSS Health, Superseded 21/09/2005 DSS specific information: The risk of coronary and other macrovascular disorders is 2-5 times higher in people with diabetes than in non-diabetic subjects and increases in parallel with the degree of dyslipidaemia. Following Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus, the targets for lipids management are:
If pre-existing cardiovascular disease (bypass surgery or myocardial infarction), total cholesterol should be less than 4.5 mmol/L Diabetes (clinical) NBPDS Health, Standard 21/09/2005 DSS specific information: The risk of coronary and other macrovascular disorders is 2-5 times higher in people with diabetes than in non-diabetic subjects and increases in parallel with the degree of dyslipidaemia. Following Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus, the targets for lipids management are:
If pre-existing cardiovascular disease (bypass surgery or myocardial infarction), total cholesterol should be less than 4.5 mmol/L |